The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYMAKER-U01 substudy 01A: Phase 1/2 study of pembrolizumab plus ifinatamab deruxtecan (I-DXd) or patritumab deruxtecan (HER3-DXd) with or without chemotherapy in untreated stage IV non–small-cell lung cancer.
 
Charu Aggarwal
Consulting or Advisory Role - Abbvie; Arcus Biosciences; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novocure; Pfizer; Sanofi/Regeneron; Takeda
Speakers' Bureau - AstraZeneca (I)
Research Funding - AstraZeneca/MedImmune (Inst); Candel Therapeutics (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Loxo@Lilly (Inst); Merck Sharp & Dohme (Inst)
 
Tibor Csoszi
Consulting or Advisory Role - Novartis
Speakers' Bureau - Ipsen; Janssen-Cilag
Travel, Accommodations, Expenses - Pfizer; Sanofi
 
Zsuzsanna Szalai
Honoraria - AstraZeneca; Berlin-Chemie; Boehringer Ingelheim; Bristol-Myers Squibb; Chiesi; Sonofi
Consulting or Advisory Role - AstraZeneca; BMS Brazil; Sanofi
Travel, Accommodations, Expenses - Berlin-Chemie; Chiesi; Sanofi
 
Jair Bar
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Janssen Oncology; Medison; Merck Serono; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Immunai (Inst); MSD (Inst); Novartis (Inst); Oncohost (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
 
Nir Peled
Honoraria - AstraZeneca Canada; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Guardant Health; Lilly; MSD; Novartis; NovellusDx; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca Canada; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Guardant Health; Lilly; MSD; Novartis; NovellusDx; Pfizer; Roche
Research Funding - MSD
 
Byoung Chul Cho
Employment - Yonsei University Health System
Leadership - J INTS BIO
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - Amgen; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BeiGene; BMS; Boehringer Ingelheim; Bridgebio; CJ bioscience; Cyrus therapeutics; Cyrus therapeutics; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Guardant Health; Harpoon Therapeutics; J INTS Bio; Janssen; Kanaph Therapeutics; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Therapex Co., Ltd; Yuhan
Research Funding - AstraZeneca; Champions Oncology; CJ bioscience; Cyrus Therapeutics; Dong-A ST; GI Innovation; ImmuneOncia; J Ints Bio; Janssen; MSD; Therapex; Vertical Bio AG; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen; PearlRiver Bio GmbH
Other Relationship - DAAN Biotherapeutics
 
Yu Jung Kim
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Bridge Biotherapeutics (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Dariusz Kowalski
Consulting or Advisory Role - Amgen; AstraZeneca Canada; BMS Brazil; Johnson & Johnson; Medison; Merck KGaA.; MSD; Pfizer; Roche; Takeda
 
Ernest Nadal
Honoraria - Apollomics; Roche/Genentech; Transgene
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Genmab; Janssen Oncology; Lilly; Merck Serono; MSD; Pfizer; Pierre Fabre; Qiagen; Roche; Sanofi; Sanofi; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Merck Serono (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche; Takeda
 
Jiaxin Niu
Consulting or Advisory Role - AstraZeneca; Bristol Mers Squibb; Daiichi Sankyo; G1 Therapeutics; Johnson & Johnson; Mirati Therapeutics; Pfizer; Sanofi; Takeda
 
Justin Gainor
Employment - Ironwood Pharmaceuticals (I)
Leadership - AI Proteins, Inc
Stock and Other Ownership Interests - AI Proteins, Inc; Ironwood Pharmaceuticals (I)
Honoraria - BeiGene; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Arcus Biosciences; Array BioPharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ellipses Pharma; EMD Serono; Genentech; Gilead Sciences; InterVenn Biosciences; ITeos Therapeutics; Lilly; Mariana Oncology; Merck; Merus; Mirati Therapeutics; Moderna Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Revolution Medicines; Sanofi; Silverback Therapeutics; Takeda; Tempus
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis; Novartis (Inst); Palleon Pharmaceuticals (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Pfizer
 
David Carbone
Consulting or Advisory Role - Abbvie; Amgen; Arcus Biosciences; AstraZeneca; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Iovance Biotherapeutics; Johnson & Johnson; Lilly; Mirati Therapeutics; MSD; Novartis; Novocure; Oncohost; Pfizer; Regeneron; Roche
 
Konstantin Dragnev
Research Funding - Amgen (Inst); Daiichi Sankyo/Astra Zeneca (Inst); G1 Therapeutics (Inst); Io Therapeutics (Inst); Lilly (Inst); Merck (Inst); Molecular Templates (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Kevin Chen
No Relationships to Disclose
 
David Sternberg
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Bin Zhao
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Heng Zhou
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Azadeh Namakydoust
Employment - Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA,\
Stock and Other Ownership Interests - Merck
 
Vamsidhar Velcheti
Honoraria - Galvanize Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Novocure; Picture Health; Regeneron; Taiho Oncology; Takeda
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); RSIP Vision (Inst); Trovagene (Inst)